These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31747739)

  • 1. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Zweck E; Westenfeld R; Szendroedi J
    N Engl J Med; 2019 Nov; 381(21):2075-2076. PubMed ID: 31747739
    [No Abstract]   [Full Text] [Related]  

  • 2. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    Husain M; Donsmark M; Bain SC
    N Engl J Med; 2019 Nov; 381(21):2076-2077. PubMed ID: 31747740
    [No Abstract]   [Full Text] [Related]  

  • 4. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):57-58. PubMed ID: 28270434
    [No Abstract]   [Full Text] [Related]  

  • 5. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
    Gomez-Peralta F; Abreu C
    Drug Des Devel Ther; 2019; 13():731-738. PubMed ID: 30863012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Lipscombe LL
    Ann Intern Med; 2019 Sep; 171(6):JC28. PubMed ID: 31525762
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral semaglutide for the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Pharmacother; 2019 Feb; 20(2):133-141. PubMed ID: 30499733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
    Ebell MH
    Am Fam Physician; 2017 Mar; 95(6):396. PubMed ID: 28318215
    [No Abstract]   [Full Text] [Related]  

  • 10. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide and GLP-1 analogues as weight-loss agents.
    Kluger AY; McCullough PA
    Lancet; 2018 Aug; 392(10148):615-616. PubMed ID: 30122306
    [No Abstract]   [Full Text] [Related]  

  • 15. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
    Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
    Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.